The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial
Authors:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Surgical Oncology
- Vol. 36, 51-55
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 13 references indexed in Scilit:
- Is there an Ideal Breast Conservation Rate for the Treatment of Breast Cancer?Annals of Surgical Oncology, 2016
- Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation RatesAnnals of Surgery, 2015
- Optimal Systemic Therapy for Early Breast Cancer in Women: A Clinical Practice GuidelineCurrent Oncology, 2015
- Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialAnnals of Oncology, 2013
- Ki-67 Index Guided Selection of Preoperative Chemotherapy for HER2-positive Breast Cancer: A Randomized Phase II TrialJapanese Journal of Clinical Oncology, 2012
- Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysisThe Breast, 2011
- Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An UpdateJournal of Clinical Oncology, 2006
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- Proto-Oncogenes and Human CancersNew England Journal of Medicine, 1987